Decoding GTN Leakage

How gross-to-net (GTN) erosion systematically destroys commercial ROI in Pharma & MedTech — and where Vamstar fits

Executive summary

• Pharma reality. The U.S. “gross-to-net bubble” (the dollar gap between manufacturer list and realized net) is vast. Brand portfolios typically realize ~40–60% of list after statutory rebates, PBM rebates/fees, 340B, channel charges, and patient programs.
• MedTech reality. Stacked GPO + IDN discounts, distributor/wholesaler service fees, returns/chargebacks, and admin/data fees commonly compress net into the 60–80% of list zone (i.e., 20–40% concessions), with higher concessions in price-competitive categories.
• Structural change deepening GTN (Pharma). From 2025, the Medicare Part D redesign requires manufacturer discounts of 10% in Initial Coverage and 20% in Catastrophic on applicable drugs, applied to the negotiated price at POS.
• Timing shift confusing forecasts (Pharma). Since 2024, DIR at POS means the negotiated price equals lowest possible reimbursement to pharmacies at the counter, re-timing GTN into the year and lowering the base for coinsurance.
• Why ROI collapses. GTN layers compound multiplicatively (not additively). A 200–300 bps miss at any stage can erase tens of millions in gross profit at scale, stretching payback and crushing IRR—even if volume meets plan.

Bottom line: GTN leakage isn’t a single drain; it’s a cascading waterfall. The only defense is stage-by-stage modeling, tight accrual governance, and net-first commercial planning.

The complete GTN waterfall (what actually happens to list price)

1) List price (WAC/ASP)

Starting point for accounting; not what you bank. The sector-wide gap between list and net keeps widening, underscoring how little list says about realized cash.

2) Statutory (mandatory) concessions — Pharma

Medicaid Drug Rebate Program (MDRP). Brand URA = max(23.1% of AMP, AMP − Best Price) + inflation penalty when AMP growth > CPI-U.

340B ceiling price. AMP − URA; covered entities must not pay above the ceiling.

Federal Ceiling Price (FCP). For Big 4/VA/DoD/PHS: ≤76% of Non-FAMP (≥24% discount) with additional adjustments.

Medicare Part D (2025→). Manufacturer discounts: 10% in Initial Coverage and 20% in Catastrophic on applicable drugs; discounts apply to the negotiated price at POS.

3) Commercial rebates & contracting

PBM/plan rebates & fees (Pharma). Deep asks in competitive classes tied to preferred placement and utilization management.

GPO admin fees & IDN overlays (MedTech). GPO savings often ~10–18%; IDNs layer local discounts/rebates and compliance incentives; vendors fund admin fees and data/reporting.

4) Channel economics

Wholesaler/distributor DSAs. Typically low single-digit % of WAC as bona fide service fees (BFSFs) for logistics, inventory, EDI/data; FMV and itemization matter to preserve exclusion from AMP/BP/ASP.

Pharmacy concessions/DIR at POS (Pharma). Negotiated price is the lowest possible reimbursement inclusive of pharmacy price concessions, shifting concessions to POS and re-timing GTN.

5) Chargebacks & returns

Chargebacks. Credits for sales below WAC under contract; leakage arises from eligibility/price-period mismatches and manual exception handling.

Returns. Low single digits steady-state; spikes at LOE/recalls; reserves need lifecycle curves.

6) Patient assistance & copay support (Pharma)

Manufacturer-funded copay/PAP materially affect net. “Accumulator/maximizer” behaviors can divert value, reducing ROI unless programs are designed to ensure the benefit reaches patients.

7) Administrative & data costs

BFSFs (wholesaler/PBM/SP services, data feeds) are excludable from government price calculations if they meet FMV, itemization, and not-passed-through tests. Weak documentation risks reclassification as price concessions.